Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Published:2020-10 Issue:10 Volume:18 Page:1385-1415
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Deininger Michael W.¹,Shah Neil P.²,Altman Jessica K.³,Berman Ellin⁴,Bhatia Ravi⁵,Bhatnagar Bhavana⁶,DeAngelo Daniel J.⁷,Gotlib Jason⁸,Hobbs Gabriela⁹,Maness Lori¹⁰,Mead Monica¹¹,Metheny Leland¹²,Mohan Sanjay¹³,Moore Joseph O.¹⁴,Naqvi Kiran¹⁵,Oehler Vivian¹⁶,Pallera Arnel M.¹⁷,Patnaik Mrinal¹⁸,Pratz Keith¹⁹,Pusic Iskra²⁰,Rose Michal G.²¹,Smith B. Douglas²²,Snyder David S.²³,Sweet Kendra L.²⁴,Talpaz Moshe²⁵,Thompson James²⁶,Yang David T.²⁷,Gregory Kristina M.²⁸,Sundar Hema²⁸

Affiliation:

1. 1Huntsman Cancer Institute at the University of Utah;

2. 2UCSF Helen Diller Family Comprehensive Cancer Center;

3. 3Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

4. 4Memorial Sloan Kettering Cancer Center;

5. 5O'Neal Comprehensive Cancer Center at UAB;

6. 6The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

7. 7Dana-Farber/Brigham and Women’s Cancer Center;

8. 8Stanford Cancer Institute;

9. 9Massachusetts General Hospital Cancer Center;

10. 10Fred and Pamela Buffett Cancer Center;

11. 11UCLA Jonsson Comprehensive Cancer Center;

12. 12Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

13. 13Vanderbilt-Ingram Cancer Center;

14. 14Duke Cancer Institute;

15. 15The University of Texas MD Anderson Cancer Center;

16. 16Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

17. 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center;

18. 18Mayo Clinic Cancer Center;

19. 19Abramson Cancer Center at the University of Pennsylvania;

20. 20Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

21. 21Yale Cancer Center/Smilow Cancer Hospital;

22. 22The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

23. 23City of Hope National Medical Center;

24. 24Moffitt Cancer Center;

25. 25University of Michigan Rogel Cancer Center;

26. 26Roswell Park Comprehensive Cancer Center;

27. 27University of Wisconsin Carbone Cancer Center; and

28. 28National Comprehensive Cancer Network

Abstract

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to aBCR-ABL1fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/18/10/article-p1385.xml

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial;Leukemia;2024-01-26

2. Erythroid variant evolving from chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors: a rare case report;Diagnostic Pathology;2024-01-24

3. 25 years of experience in the treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: results, opportunities, questions;Meditsinskiy sovet = Medical Council;2024-01-17

4. Maximizing the Value of Chronic Myeloid Leukemia Management Using Tyrosine Kinase Inhibitors in the USA: Potential Determinants and Consequences of Healthcare Resource Utilization and Costs, with Proposed Optimization Approaches;Clinical Drug Investigation;2024-01-05

5. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT);Transplantation and Cellular Therapy;2024-01